IP Library Patent Application 13337621
Patent Application
App. No. 13/337,621

TISSUE MAINTENANCE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
13/337,621
Abstract

The invention provides a method of reducing damage to a tissue, organ or cell from surgical procedures comprising administering a composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist (eg. adenosine) together with a local anaesthetic (eg. lignocaine) when perfusing the organ.

Claims (12)

1 - 16 . (canceled)

17 . A method of reducing damage to a tissue, organ or cell from periods of reduced activity comprising administering when reperfusing the organ during the recovery phase an additive composition comprising a potassium channel opener/agonist and/or an adenosine receptor agonist, together with a local anaesthetic.

18 . A method according to claim 17 , wherein the composition further includes elevated magnesium cations in an amount of from about 0.5 mM to about 20 mM.

19 . A method according to claim 17 , wherein the composition is heated to a temperature of from about 32° C. to about 37° C. before administration.

20 . A method according to claim 17 , wherein the reduced activity is medically induced.

21 . A method according to claim 17 , further comprising administering the additive composition while perfusing the organ during a quiescent state.

22 . A method according to claim 17 , wherein the organ is a heart and the reduced activity is cardioplegic arrest.

23 . A method according to claim 17 , wherein the composition comprises a potassium concentration of less than about 10 mM.

24 . A method according to claim 17 , wherein the potassium channel opener/agonist is adenosine and the local anaesthetic is lignocaine.

25 . A method according to claim 17 , wherein the additive composition comprises adenosine, magnesium cations and lignocaine.

26 . A method according to claim 17 , wherein the damage to a tissue organ, or cell comprises post-operative fibrillation that occurs following a heart procedure.

27 . A method according to claim 17 , further comprising reanimating the tissue, organ or cell.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2014
From: HIBERNATION THERAPEUTICS LTD
To: HIBERNATION THERAPEUTICS GLOBAL LTD
Reel/Frame 033375/0319 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 23, 2014
From: HIBERNATION THERAPEUTICS GLOBAL LTD
To: HIBERNATION THERAPEUTICS, A KF LLC
Reel/Frame 033375/0359 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2012
From: DOBSON, GEOFFREY PHILIP
To: HIBERNATION THERAPEUTICS LIMITED
Reel/Frame 027825/0708 →